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doi:10.1016/j.ejvs.2010.11.021Abstract Objective: Annexin A1, a calcium and phospholipid-binding protein, is an important
endogenous modulator of inflammation. Whether this regulatory role extends to atheroscle-
rosis is unknown. The aim of this study is to investigate the genetic and protein expression
of Annexin A1 in carotid endarterectomy specimens from patients with significant carotid
stenosis.
Materials and methods: The echogenicity of atherosclerotic plaques was determined by ultra-
sound prior to carotid endarterectomy (CEA) in 34 consecutively recruited patients with
carotid stenosis exceeding 70%. The Annexin A1 messenger RNA and protein expression of
the corresponding plaques obtained from those patients were analyzed by reverse transcrip-
tase polymerase chain reaction (RT-PCR) and the immunohistochemical method respectively.
Results were analyzed with respect to plaque characteristics and symptomatic disease.
Results: There were 25 males and 9 females, with a mean age of 68.8. Ten patients were
asymptomatic. The symptomatic patients’ plaques were more echolucent (mean grey scale
median (GSM) of 103) than those of asymptomatic patients (mean GSM Z 126, p Z 0.022).
The Annexin A1 protein was constitutively expressed in all plaques, and Annexin A1 gene
expression was statistically higher in patients with asymptomatic disease compared with those
with neurological symptoms (87  4% vs. 42  6.2%; p < 0.001, unpaired t-test). The GSM score
was positively correlated with Annexin A1 levels in patients with high-grade carotid artery
stenosis (r Z 0.501, p Z 0.009).
Conclusions: This is the first study to suggest that high Annexin A1 expression may have a sta-
bilising effect in asymptomatic patients with less echolucent atherosclerotic plaques. Since
atherosclerosis is an inflammatory process, we further postulate that Annexin A1 may play
an essential role in preventing plaque complications or disease progression.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.2255 4962; fax: þ852 2255 4961.
(S.W.K. Cheng).
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are due to microemboli generated from carotid athero-
sclerotic plaques.1 Thus, the stability of the plaque dictates
whether the patient will develop symptoms. Specifically,
echolucent plaques that are lipid rich tend to develop
complications and may rupture to contribute to symptom-
atic neurological events independent of the degree of
stenosis.2
To date, carotid endarterectomy (CEA) is one of the
most scrutinised surgical procedures, and it has been shown
by multicentre trials to be effective in the prophylaxis
against strokes, if the degree of stenosis is greater than
70%.3e6 The biological examination of CEA specimens may
therefore provide invaluable information regarding the
cellular and molecular events leading to plaque rupture.
Immunohistochemical studies of plaque have shown that
one of the major determinants of plaque rupture is fibrous
cap inflammation.7 In the advanced stages of carotid
stenosis, a low concentration of vascular smooth muscle
cells (VSMCs),8 and an increased concentration of macro-
phages and inflammatory cells in the fibrous cap weakens
the plaque, causing plaque rupture.9 In addition, failed or
delayed clearance of apoptotic cells can result in the
chronic inflammation that characterises carotid stenosis.10
The in vivo clearance of apoptotic cells is also found to
enhance the release of anti-inflammatory cytokines.11
Thus, phagocytosis of apoptotic cells probably plays
a pivotal role in the resolution of inflammation that may
stabilise the atherosclerotic plaque.
Annexin A1 belongs to a group of calcium-dependent,
phospholipid-binding proteins that have been implicated in
diverse cellular roles, including the control of inflammatory
responses, membrane fusion, and cell differentiation and
proliferation.12,13 Annexin A1 was originally identified in
leucocytes as a glucocorticoid-inducible protein that
inhibits phospholipase A2, thus preventing the formation of
pro-inflammatory eicosanoids,14 and it has been shown to
mimic the anti-inflammatory actions of glucocorticoids in
many experimental models.15
Annexin A1 is also found to be a powerful phagocytotic
protein that can dampen inflammatory responses by allowing
safe post-apoptotic clearance of dead cells.16 The Solito
et al. research group also found that Annexin A1 may inhibit
leucocyte migration by impairing neutrophil and monocyte
adhesion to vascular endothelium, thus inducing apoptosis of
inflammatory cells. All these effects contribute to the
potent anti-inflammatory action exerted by both Annexin A1
and its induced proteins.14 More recent research indicated
that Annexin A1 has been indirectly linked to atherogenesis
through the engulfment of apoptotic bodies present in the
coronary atherosclerotic plaque.17 The author suggested
that the engulfment of apoptotic cell is the factor involved in
the development and progression of atherosclerosis.
However, Annexin A1 involvement in human atherosclerosis
development, particularly in carotid stenosis, remains
unknown.
Given the potential anti-inflammatory effect of Annexin
A1 that could stabilise carotid plaques, we hypothesise that
enhanced Annexin A1 protein expression in human asymp-
tomatic plaques will stabilise carotid plaques via an anti-
inflammatory mechanism. Thus, its expression may be
beneficial as an endogenous defence with respect to theinflammatory stimuli that are released in the plaque. To
test this hypothesis, carotid plaque specimens from both
asymptomatic and symptomatic patients were examined
using molecular biological approaches and immunohisto-
chemical analysis. The association of plaque echolucency
and detection of macrophages with Annexin A1 gene
expression levels was also investigated. We expect this
study to provide more biochemical information on carotid
plaques. Understanding the role of the powerful anti-
inflammatory actions of endogenous Annexin A1 compounds
may be a useful tool in the development of potential
therapeutics for resolving atherosclerotic carotid stenosis.
Methods
Patient recruitment
Between June 2003 and June 2009, 34 consecutive patients
(25 male, nine female), who were attributed as having
a high-grade (70%) atherosclerotic stenosis of carotid
artery that was revealed ultrasonically and who underwent
CEA, were recruited for the study. The study protocol was
approved by the institutional review committee and
informed consent was obtained from the patients.
Carotid plaque ultrasonic characteristics
Carotid plaque characteristics were studied by ultrasonog-
raphy before CEA surgery in all consecutive patients. The
corresponding carotid plaque echogenicity was measured by
a method described previously,18 and modified for our
laboratory scanner.19 The plaque was outlined and the
distribution of the grey levels within the plaque was
assessed. The digitised images were converted to grey scale,
and the level normalised with a 256 greyscale range with
respect to bloodZ 0e5, maximal white according to a linear
reference scaleZ 256. This would give a greyscale value of
the adventitia of approximately 230. The plaque outline was
mapped manually using commercial image processing soft-
ware (Adobe Photoshop 5.0) and the greyscale histogramwas
calculated. Data regarding the grey scale median (GSM), and
its standard deviation (homogenicity), were obtained from
the histogram.
Carotid plaque collection
The corresponding plaques were excised at the time of CEA
surgery in a sterile fashion without damage to the plaque
surface. Ulcerated plaques and intraplaque haemorrhage
are likely to contribute to symptomatic disease.20 Patients
with evidence of a >70% stenosis in the common or internal
carotid arteries on duplex ultrasound and who gave
a history of cerebrovascular symptoms (such as stroke,
transient ischaemic attacks or amarousis fugax) prior to the
carotid duplex ultrasound examination were classified as
symptomatic. No haemorrhaging was found in any of the
studied specimens. Five of the symptomatic plaques with
an ulcerated luminal surface were excluded to maintain the
homogeneity of the plaque specimens. All plaques were
divided into two parts at the most prominent site of the
plaque. One part was fixed for 24 h in buffered formalin and
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while the other part was rapidly frozen in liquid nitrogen
and then stored at 80 C until further processing for
ribonucleic acid (RNA) extraction.
Serum sample collection
Clotted bloods were prepared conventionally from each
patient at the time of presentation, aliquoted and stored at
80 C until the enzyme-linked immunosorbent assay
(ELISA) was performed.
Immunohistochemistry for Annexin A1
Annexin belongs to a family of structurally related calcium-
and phospholipid-binding proteins that includes Annexin
A1, A2 and A5. The anti-inflammatory effects are mainly
attributed to the multifaceted Annexin A1, while Annexin
A5 is found to be an apoptotic factor. Preliminary staining
results found no Annexin A2 or A5 protein in either type of
plaque. Therefore, in the present study, we only focussed
on Annexin A1. The 5-mm-thick paraffin-embedded plaque
sections were cleared and rehydrated by sequential
immersions in three changes of xylene, followed by graded
ethanol and distilled water. For antigen retrieval, tissues
were heated by microwave treatment in 0.01 M citrate
buffer for 90 s. After cooling, slides were incubated with
anti-Annexin A1 (Santa Cruz Biotechnology Inc, Santa Cruz,
CA, USA) at a 1:200 dilution for 60 min, and subsequently
incubated with the peroxidase-labelled secondary antibody
(Dako, Carpinteria, CA, USA). Sections were detected by
the Dako EnVision Visualization System (Dako, Carpinteria,
CA, USA) with diaminobenzidine used as the chromogenic
substrate. Staining development was stopped by immersion
in tap water and counterstained with LillieeMayer haema-
toxylin (Merck, Darmstadt, Germany). All slides were then
dehydrated and cleared by sequential immersion in
gradient ethanol and xylene. Negative control was always
performed by omitting primary antibody. All stained slides
were viewed under light microscope (Olympus, Leeds
Precision Instruments) and pictures were taken with an
imaging program.
RNA extraction
All plaque specimens were pulverised under liquid nitrogen,
and total RNA was extracted using the TRIzol LS Reagent
(GIBCO BRL, Rockville, MD, USA).
To evaluate the quality of RNA, absorbency at 260/
280 nm was determined by spectrophotometry. Approxi-
mately 1 mg of each sample was loaded onto the agarose gel
and resolved by electrophoresis. The gel was stained with
ethidium bromide. The 18S and 28S bands were visualised
using ultraviolet (UV) light.
Reverse transcriptase-polymerase chain reaction
(RT-PCR)
Two micrograms of total RNA of each sample was used to
synthesise the first-strand complementary DNA (cDNA) with
the SuperScript Preamplification System for First StrandcDNA Synthesis Kit (GIBCO BRL, Rockville, MD, USA). Then,
1 ml of the reverse transcriptase (RT) product was used as
the template to amplify specific Annexin A1 fragments. The
polymerase chain reaction (PCR) conditions were optimised
individually for each gene studied, and the cycle number for
PCR was adjusted to 30, so that the reactions fell within the
linear range of product amplification. The expression of the
housekeeping gene, b-actin, was used as an internal
control. The RT-PCR product was analyzed by electropho-
resis on a 2% agarose gel and confirmed by sequencing using
an Automatic Sequencer. Signal intensities were quantified
using densitometry (Bio-Rad Laboratories, Hercules, CA,
USA). The Annexin messenger RNA (mRNA) level was quan-
tified by the intensity ratio of the target signal to the b-actin
control under the same PCR reaction conditions. The
Annexin A1 primer sequences of the PCR were 50-TAAGC-
GAAACAATGCACAGC-30and 50-CAAAGCGTTCCGAAAATCTC-
30 with a product size of 331 bp. The b-actin primer
sequences were 50-GCCATCCTGCGTCTGGACCTGGCT-30and
50-GTGATGACCTGGCCGTCAGGCAGC-30, with a product size
of 181 bp.
Detection of inflammatory macrophages
To investigate the inflammatory status of the studied pla-
ques, the corresponding sections were also incubated with
human anti-macrophage (Dako, Carpinteria, CA, USA) for
1.5 h at 37 C and detected by the same staining procedure.
Representative microscopic fields of the plaque specimens
were chosen under low-power light microscopy. To avoid
underestimating the quantity of macrophages in the plaque
specimens due to regional variation, only areas with the
largest number of macrophages were chosen. The number
of positive-stained macrophage cells was measured for 10
contiguous 200 high-power fields for each sample. The
overall mean of macrophage cells for each specimen was
determined as macrophages per high-power field.
Measurement of inflammatory cytokines
Serum levels of inflammatory cytokines including inter-
leukin (IL)-1b, IL-6, IL-8 and IL-10 of the study patients
were measured by standard ELISA kits (Quantikine Human
IL-1b, IL-6, IL-8 and IL-10m R & D Systems Ltd, Abington,
UK).
Statistical analysis
Continuous data (age) were expressed as a mean, and range
and categorical data were expressed as percentages. The
intima media thickness (IMT) GSM and GSM standard devi-
ation (homogenicity), the degree of stenosis and the
common and internal carotid artery lumen values were
normally distributed and compared for asymptomatic and
symptomatic patients using Student’s unpaired t-test
(SPSS14.0, Inc., Chicago, IL, USA). Comparison of Annexin
A1 expression between the two groups of plaques was also
carried out using Students T-test. The Pearson correlation
test was used to assess the correlation between echoge-
nicity, macrophage numbers and Annexin A1 gene expres-
sion. Differences at p < 0.05 were considered significant.
Table 1 Demographics and atherosclerosis risk factors of
34 carotid endarterectomy (CEA) patients.
Asymptomatic
Patients
Symptomatic
Patients
No. of patients 10 24
Age (mean) 72.07 69.5
Age (range) 48e82 57e77
Male (%) 70% 75%
Smoking (%) 50% 50%
Hypertension (%) 70% 75%
Diabetes Mellitus (%) 30% 41.7%
Hyperlipidemia (%) 50% 58.3%
Ischemic Heart Disease (%) 20% 75%
Peripheral arterial
occlusive disease (%)
2% 16.7%
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Characteristics of the patients
In this study, 10 and 24 patients were classified as asymp-
tomatic and symptomatic patients, respectively. Carotid
plaque imaging and quantification of plaque echogenicity
was feasible in all patients. The characteristics of all
patients are summarised in Table 1. There was no signifi-
cant difference between asymptomatic and symptomatic
patients in terms of gender, age and atherosclerotic risk
factors, except the co-existence of ischaemic heart disease
and other vascular diseases.
Characteristics of plaques and carotid artery walls
The ultrasonic plaque characteristics are stated in Table 2.
The homogenicity of the plaque did not differ significantly
between the two groups. The echogenicity of the studied
carotid plaques was widely distributed, ranging from more
echolucent to downright echogenic (range from 93 to 155).
The symptomatic patients’ plaques were echolucent (mean
GSM of 103) than those of asymptomatic patients (mean
GSM of 126, pZ 0.022). They also exhibited a higher degree
of luminal stenosis (85% vs. 71.4%, p Z 0.018).Table 2 Plaque characteristics, carotid arterial lumen
and wall thickness in patients with asymptomatic and
symptomatic carotid stenosis disease.
Carotid artery
Parameter
Asymptomatic
patients
(n Z 10)
Symptomatic
patients
(n Z 24)
p value
IMT (mm) 0.94  0.3 1.02  0.15 0.628
CCA lumen (mm) 5.33  0.25 5.87  0.48 0.172
ICA lumen (mm) 4.74  0.4 4.92  0.57 0.169
Stenosis (%) 71.4  3.87 85  6.33 0.018
GSM (echogenicity) 126  7.18 103  7.9 0.022
GSM-SD
(homogenicity)
0.97  2.7 46  2.17 0.066Quantification of macrophages
Morphometric analysis demonstrated that there were
significantly more macrophages in symptomatic plaques as
compared with asymptomatic plaques (Table 3, p Z 0.01).
This difference persisted even after the macrophage
numbers were normalised to the plaque area (6  1.11 vs.
15.4  2, p < 0.01). The GSM score correlated with numbers
of macrophages (Pearson coefficient rZ 0.52, p < 0.05).
More macrophages were therefore found in the more
echolucent plaques.
Expression of Annexin A1 protein
Annexin A1 protein was expressed in all atherosclerotic
plaques, particularly the plaques from asymptomatic
patients. Fig. 1 shows the representative immunohisto-
chemical staining pictures of Annexin A1 in asymptomatic
plaques. In the control experiment, the Annexin A1 anti-
body was omitted in the staining procedures (40) (Fig. 1
(a)). Prominent Annexin A1 immunoreactivity was
expressed in asymptomatic plaques (40) (Fig. 1(b)). Fig. 1
(c) shows Annexin A1 expression in symptomatic plaques
(100) and Fig. 1(d) shows the higher magnification image
(100) of Annexin I expressed in asymptomatic plaques.
Expression of Annexin A1 mRNA
Fig. 2 shows the representative gel photograph of Annexin A1
expression in both types of tissues. Fig. 3 shows the summary
of the relative expression of Annexin A1 in all plaques spec-
imens after normalisation with the b-actin expression from
the same mRNA template. The plaque expression levels of
the Annexin A1 gene in asymptomatic patients were signifi-
cantly higher than symptomatic patients (87  4% vs.
42  6.2%, p < 0.001). The Annexin A1 gene was found to be
inversely correlated with the numbers of macrophage
detected in plaques (rZ 0.46, p < 0.05) (Fig. 4).
Measurement of inflammatory cytokines
Among all studied cytokines levels (IL-1b, IL-6, IL-8 and IL-
10) detected in the serum samples, only IL-6 was signifi-
cantly increased in the serum of symptomatic patients as
compared with that of asymptomatic patients (Table 4,
230  15 vs. 90  20 pg ml1, p < 0.001).
Discussion
The present study demonstrated for the first time that
Annexin A1 is strongly expressed within the plaques obtainedTable 3 The number of macrophages found in asymp-
tomatic and symptomatic plaque specimens.
Type of plaque
specimens
n No. of Macrophage p value
(1) Asymptomatic 10 15  8.5 e
(2) Symptomatic 24 20.5  5 0.01
Figure 1 Immunohistochemical staining of Annexin I protein in all atherosclerotic plaques. In the control experiment, the
Annexin I antibody was omitted in the staining procedures (A). More pronounced Annexin I, was found particularly in asymptomatic
plaques (B) than symptomatic plaques (C). Figure D showing the higher magnification picture (100) of Annexin I expressed in
asymptomatic plaques.
368 B.L.Y. Cheuk, S.W.K. Chengfrompatientswith advancing carotid stenosis, illustrating the
relationship between Annexin A1 and advanced atheroscle-
rosis. Although atherosclerotic plaque instability is deter-
mined by multiple factors, the inflammatory pathways have
a particularly significant role.21 Annexin A1 has been sug-
gested to play an important part in anti-inflammation by
engulfing apoptotic cells and allowing safe post-apoptotic
clearance of dead cells.22 It also blocks the release of
inflammatory mediators by directly inhibiting cytosolic
phospholipase A2
14 and the expression and activity of otherFigure 2 Representative RT-PCR gel photos showing the
Annexin A1 mRNA expression in both asymptomatic and
symptomatic plaque specimens. Higher Annexin A1 expression
was found in asymptomatic plaques as compared with symp-
tomatic plaques.inflammatory mediators such as cyclooxygenase,15 IL-6,23 IL-
10 and inducible nitric oxide synthase (iNOS).24 Thus, the
higher Annexin A1 expression in plaques obtained from
asymptomatic patients as compared with that in symptom-
atic patients may act as a local protective factor in response
to the inflammatory stimulus that releases in the plaques.
This action is hypothetically beneficial in stabilising the pla-
ques in carotid stenosis patients.
Atherosclerosis is a chronic inflammatory disease occur-
ring within the artery wall. Macrophages are an inflammatory
featureof plaques and are found to be involved in all stages of
plaque development. We stained macrophage cells in the
plaque specimens, rather than studying the macrophage
serologically. As most studies detected the macrophages in0
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Figure 3 The histogram shows the Annexin A1 mRNA
expression expressed as means  S.D of the 34 studied plaques.
The statistical difference was p < 0.001 when comparing the
two types of plaques.
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Figure 4 Human carotid plaque echogenicity measured by
ultrasound correlated positively with the Annexin A1 gene
expression with the Pearson correlation coefficient r Z 0.501,
p Z 0.009.
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direct measurement of macrophage in the plaque for indi-
cating the inflammation status,24,25 the current immunohis-
tochemical analyses become a more direct and promising
indication of inflammatory events in the carotid plaques, as
the systemic release of inflammatory factors is probably not
an exact reflection of vascular cell levels.24 Our findings are
consistent with those of Pilarczyk et al.26 and Seshiah et al.8
which show that macrophages are found to a greater extent
in symptomatic plaques than in asymptomatic plaques.
Macrophages canweaken plaque stability by secretingmatrix
metalloproteinases27,28 and releasing inflammatory cyto-
kines.21 The accumulation of macrophages has also been
correlated with plaque ulceration and thrombosis29 and the
degree of stenosis,30 and it would shift the balance of VSMC
survival vs. apoptosis.31 These phenomena further confirm
that there is an intense inflammatory response in our symp-
tomatic plaques that may lead to plaque instability.
Inflammation and apoptosis are both critical factors
related to the atherosclerotic process and plaque insta-
bility.7,9 Our results of the anti-inflammatory Annexin A1Table 4 ELISA data of all studied inflammatory cytokines
in the serum of all both groups of patients. There were 10
asymptomatic and 24 symptomatic patients. IL-6 levels
detected in the blood samples of symptomatic patients
were greater than in that of asymptomatic groups
(p < 0.001). Statistically comparisons between the two
groups were also indicated.
Patients group
Inflammatory
cytokines
(pg/ml)
Asymptomatic
(n Z 10)
Symptomatic
(n Z 24)
P-value
IL-1b 75  29 80  16 Not significant
IL-6 90  26 230  15 0.001
IL-8 150  12 105  55 Not significant
IL-10 126  95 135  78 Not significantprotein expressed in the stable plaques of asymptomatic
patients may supplement the results of Dhume et al. in the
sense that the expression of the anti-apoptotic Bcl-2 family
proteins were increased in the plaques from asymptomatic
carotid stenosis patients rather than in the plaques of the
symptomatic patients.7 Foam cell apoptosis has been linked
to plaque destabilisation and thrombus formation, with
subsequent development of acute ischaemic events. Thus,
the anti-inflammatory action of Annexin A1, accompanied
with the anti-apoptotic Bcl-2 protein, should be critical in
stabilising the plaques. The regulatory process to guard the
expression of anti-inflammatory and anti-apoptotic
proteins definitely needs further investigation.
Collectively, enhanced Annexin A1 expression is believed
to induce an anti-inflammatory effect by clearing apoptotic
cells, inhibiting inflammatory enzymes expression and then
promoting VSMC proliferation in the asymptomatic plaque.
Local expression of macrophages represents the systematic
state of inflammation of plaque, while the plaque Annexin
A1 expression may represent the local protective mecha-
nism with anti-inflammatory property. Another cardiovas-
cular team also found a fivefold increase in Annexin A1 in
Apolipoprotein E-deficient mice than in the wild type.32
This could explain why patients with symptomatic cere-
brovascular diseases demonstrate higher Annexin A1
expression. If this is the case, then modifying Annexin A1
expression may be beneficial in stabilising the atheroscle-
rotic plaque and may become a therapeutic agent in future
medicine.
All recruited patients had high-grade internal carotid
artery (ICA) stenosis because all were candidates for CEA,
although the degree of stenosis was related to the occur-
rence of symptoms in the present study (71.4% vs. 85%,
p Z 0.018). Thus, the possibility of the severity of stenosis
being the confounding factor of high Annexin A1 plaque
levels cannot be neglected.
Carotid atherosclerosis with echolucent plaque is closely
related to the occurrence of cerebral infarction.2 Deter-
mining not only the severity of carotid stenosis but also the
features of the plaque by means of high-resolution ultra-
sound and studying the composition of the atherosclerotic
plaque becomes important in defining cardiovascular risk.29
In the present study, harvesting all plaques and quantifying
their echogenicity offers a good and promising opportunity
to explore the possible mechanisms that unstabilise the
plaque and cause rupture. Notably, the GSM score was
associated with plaque Annexin A1 expression, indicating
that the echolucent plaques had less beneficial Annexin A1.
Patients with less plaque Annexin A1 may become more
vulnerable, resulting in strokes and bringing about disability
and mortality. Therefore, the reduced levels of Annexin A1
may be a marker of plaque instability and increased echo-
lucency in carotid plaques, potentially reflecting the
significant pathogenic process in these patients.
The constitutively expressed Annexin A1 within all pla-
ques suggests that this is a common response to the local
inflammatory reaction. Xin’s cDNA microarray study has
yielded results consistent with their staining results, sug-
gesting that Annexin A1 regulation occurs at the tran-
scriptional level.33 This should be the same case in the
present Annexin A1 analysis where both gene and protein
are expressed in our carotid plaques. Nonetheless, the
370 B.L.Y. Cheuk, S.W.K. Chengpresent study is only an observation study. Thus, no causal
relationship between enhanced Annexin A1 and athero-
thrombotic events in advanced carotid plaques can be
found.
Our results of Annexin A1 expression levels with respect
to symptomatology and echogenicity can provide an insight
into the morphological correlation of plaque instability.
Higher Annexin A1 expression was probably triggered to act
as a protective factor against a series of inflammatory
events to stabilise the plaques and prevent plaque rupture.
This could explain partly why echogenic plaques in
advanced stenosis patients without neurological symptoms
have higher Annexin A1 expression. However, this is
a single-centre study with relatively less patients involved.
Recruiting more patients or conducting multicentre studies
would be particularly useful to further validate the present
observation. Hope future studies can be warranted to
reveal new molecular targets for therapeutic applications
in stabilising atherosclerotic plaques.
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